Researchers from the University of South Florida (USF) have identified bacterial toxins within Antarctic sea squirts that show potential as a treatment for melanoma, the deadliest form of skin cancer. According to USF chemistry professor Brian Baker, the toxins—originally developed by the invertebrates for defense against predators—successfully eliminated melanoma cells in mice during initial trials without harming the host animals.
How Antarctic Marine Life Could Combat Melanoma
The discovery centers on ascidians, small marine invertebrates that thrive in the extreme, icy environments of Antarctica. A USF research team, funded by the National Science Foundation, spent six weeks collecting these organisms at depths reaching 130 feet. Brian Baker reports that the team’s laboratory work confirmed the toxins possess the physiological properties required for drug development, specifically the ability to target and kill cancer cells.
What Challenges Remain Before Human Trials?
While the initial results in mice are promising, the path to a clinical treatment is lengthy. Baker notes that the primary hurdle is material quantity. A basketball-sized collection of ascidians yields only about one-thousandth of the amount of toxin required for large-scale animal studies. Because harvesting such large quantities from the Antarctic would damage the local ecology, researchers are focused on developing methods to synthetically reproduce the toxin in the laboratory.
Beyond synthesis, the drug must undergo a rigorous, multi-year succession of regulated trials. Ben Meister, a USF professor and the expedition’s diving safety officer, emphasizes that the research is already complex due to the environment. Divers faced leopard seals, shifting sea ice, and low visibility during the collection process, requiring meticulous safety planning for every 30-minute dive.
How Are Researchers Advancing the Science?
The USF team is currently collaborating with the Desert Research Institute and the Scripps Institution of Oceanography to refine the development process. Baker explains that the most recent expedition provided vital data on the ecological relationship between the ascidians and the bacteria that produce the toxins. This understanding is intended to guide future drug formulation, helping scientists identify which biological pathways to target and which to avoid.
The project represents a professional goal for Baker, who has evaluated undersea organisms for healthcare applications since 1990. He characterizes the successful elimination of cancer cells in mice as a “career pinnacle,” though he acknowledges that transitioning from petri dish results to human medicine requires clearing significant regulatory and scientific hurdles.
Frequently Asked Questions
- Why were these organisms collected in Antarctica?
Antarctic marine life, such as ascidians, produce unique chemical defenses against predators in extreme conditions, which researchers believe can be repurposed for medical treatments. - Are human trials currently underway?
No. The research is currently in the laboratory stage, focusing on synthetic reproduction of the toxin and further animal model testing. - Who funded this expedition?
The research was funded by the National Science Foundation.
Have questions about the latest developments in marine biotechnology? Sign up for our weekly science newsletter to receive updates on this study and other breakthroughs in cancer research.
Related reading
